Tuesday, October 15, 2019
    Latest

    AbbVie

    Home AbbVie
    Kaiser Permanente Participating in AbbVie-Sponsored International Clinical Trial Targeting Ovarian Cancer with PARP Inhibitor Called Veliparib
    AbbVie

    Kaiser Permanente Participating in AbbVie-Sponsored International Clinical Trial Targeting Ovarian Cancer...

    0
    A Rapidly Competitive Space
    AbbVie

    AbbVie Acquires Seattle Area Start-Up to Further Bolster Its Early Stage...

    0
    Abbvie Merger
    AbbVie

    AbbVie Will Acquire Allergan in $63 Billion Merger

    0
    Multiple Myeloma PharmaWatch
    AbbVie

    AbbVie Resumes CANOVA Multiple Myeloma Trial After FDA Lifts Partial Hold

    0
    Novel Combo Drug Effective Against AML
    AbbVie

    VCU Massey Cancer Center Identifies Novel Combo Drug Effective Against AML...

    0
    AbbVie
    AbbVie

    AbbVie Active at ASCO with Over 40 Abstracts Highlighting its Oncology...

    0
    AbbVie

    AbbVie’s Treatment for Plaque Psoriasis, Skyrizi, Approved by FDA

    0
    AbbVie

    AbbVie Treatment Approved For Moderate to Severe Psoriasis

    0
    AbbVie
    AbbVie

    AbbVie Walks Away from Inflammatory & Autoimmune Drug Dev Partnership

    0
    AbbVie

    Hidradenitis Suppurativa Patient Website: Does It Live Up to Its Name?

    0
    12Page 1 of 2
    - Advertisement -

    EDITOR PICKS

    TrialSite News is the only digital media dedicated 100% to transparent and open coverage of clinical research trial sites around the globe. Based in the Silicon Slopes in downtown Salt Lake City, Utah, we are founded by a team of experts in the clinical trials industry and dedicated to transparency, quality and clinical trial innovation.

    159 West Broadway Suite 200
    Salt Lake City, UT 84101

    Contact us: admin@trialsitenews.com
    © TrialSite News, Inc. All Rights Reserved